Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

The drug is already approved for KMT2A-rearranged AML, and Syndax is hoping for approval in NPM1-mutated disease by the end of the year.